AXIM® Biotech Expands Advisory Board to Broaden the Development of Cannabinoids' Therapeutic Indications

NEW YORK, Dec. 29, 2016 -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in biotechnology cannabinoid research and development, announced today the addition of renowned Cardiac Anesthesiologist, Dr. Emil Engels MD, MBA, CPC. Dr. Emil Engel serves as Partner at Fairfax Anesthesiology Associates and American Anesthesiology of Virginia.

Dr. Emil Engels, joins AXIM® Biotech’s Board of Advisors.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/7233bf6b-b80e-4b17-8d4e-2a58243d4d1f

“We are extremely pleased that Dr. Engles has agreed to join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “Dr. Engels will advise us on our post-herpetic neuropathy, restless leg syndrome and other neurodegenerative and pain IP developments and clinical programs. Furthermore, he will advise on the development of our analgesia program to broaden cannabinoid-based therapeutic indications.”

Dr. Emil Engels, MD, MBA, CPC received his medical degree from Yale University, and did his residency at Brigham and Women’s Hospital in Boston, Massachusetts. He completed additional fellowship in cardiac anesthesia at Harvard Medical School, and is currently a Partner at Fairfax Anesthesiology Associates and American Anesthesiology of Virginia.

Dr. Engels earned an MBA from the University of Tennessee. He also holds a Lean Six-Sigma Certification and is a Certified Professional Coder.

He also serves as Corporate Compliance Officer for Fairfax Anesthesiology Associates, and serves on the Mednax Corporate Coding and Compliance Committees. Dr. Engels serves on the following ASA committees: Committee of Economics and the Committee on Large Group Practices. He is currently the President-Elect of the Virginia Society of Anesthesiologists (VSA). In addition, Dr. Engels participates on the Medicare Carrier Advisory Committee for Novitas.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM^® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
[email protected]
www.cmwmedia.com

Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227